Publication | Open Access
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
217
Citations
30
References
2019
Year
Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS.
| Year | Citations | |
|---|---|---|
Page 1
Page 1